A major pharmaceutical intermediate project began in the Duguimala Industrial Park in Hangjinqi, Ordos on Aug 6.

The project received 600 million yuan ($85.43 million) in investment from Zhejiang Huazhou Pharmaceutical Co Ltd, Jinquan Biotechnology Co Ltd, and Inner Mongolia Sihai Pharmaceutical Co Ltd. 

The first phase of the project is expected to attract 350 million yuan in investment and will mainly produce atorvastatin calcium, a global blood lipid lowering drug, and analgesic anti-etotype acid intermediates. 

It will also become the world’s only producer of acid amiloride hydrochloride intermediate 3–carboxylic, a diuretic drug. 

The project is expected to produce 36,000 tons of pharmaceutical intermediates worth 2.8 billion yuan every year and pay 300 million yuan in local taxes.   

Its products will be sold to a number of countries and regions, including the United States, Britain, and Germany. 

The pharmaceutical intermediate project of Zhejiang Huazhou Pharmaceutical Co Ltd began in the Duguimala Industrial Park in Hangjinqi, Ordos on Aug 6. [Photo/WeChat account of ordosnews] 

The project received 600 million yuan ($85.43 million) in investment from Zhejiang Huazhou Pharmaceutical Co Ltd, Jinquan Biotechnology Co Ltd, and Inner Mongolia Sihai Pharmaceutical Co Ltd. [Photo/WeChat account of ordosnews]